Literature DB >> 20394726

The pattern of human tau phosphorylation is the result of priming and feedback events in primary hippocampal neurons.

J Bertrand1, V Plouffe, P Sénéchal, N Leclerc.   

Abstract

Tau, an axonal microtubule-associated protein, becomes hyperphosphorylated in several neurodegenerative diseases including Alzheimer disease (AD). In AD brain, tau is phosphorylated at pathological multiple-site epitopes recognized by the antibodies AT8 (S199/S202/T205), AT100 (T212/S214/T217), AT180 (T231/S235) and PHF-1 (S396/S404) and at individual sites such as S262 and S422. Although it is believed that the hyperphosphorylation of tau occurs in a precise cascade of phosphorylation events, this cascade remains to be demonstrated in mammalian neuronal cells. In the present study, human tau mutants in which disease-related sites associated with either an early (AT8, T231 and S262) or intermediate (T217) stage of tau pathology were mutated in alanine to inhibit their phosphorylation were overexpressed in primary hippocampal neurons to examine their impact on the phosphorylation of other disease-related sites. The mutation in alanine of S262 decreased the phosphorylation of the AT8 and PHF-1 epitopes and that of T217. When the sites included in the AT8 epitope were mutated in alanine, the phosphorylation of T217 and PHF-1 epitope was significantly reduced indicating that the decrease of AT8 phosphorylation was a key event in the impaired phosphorylation of T217 and PHF-1 by the S262 alanine mutant. Most interestingly, the mutation in alanine of T217 had a positive impact on the phosphorylation of the AT8 epitope, indicating the presence of a feedback loop between AT8 and T217 in rat hippocampal neurons. The phosphorylation of the AT180 epitope was increased when S262 and the sites forming the AT8 epitope were mutated in alanine. The mutation of the AT8 epitope also increased the phosphorylation of S422. All together, our data show that the sites forming the AT8 epitope could play a central role in regulating the phosphorylation of tau at disease-associated sites and that priming and feedback events take place to regulate the overall level of tau phosphorylation in rat hippocampal neurons. 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20394726     DOI: 10.1016/j.neuroscience.2010.04.009

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  24 in total

1.  Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Authors:  Brian R Hoover; Miranda N Reed; Jianjun Su; Rachel D Penrod; Linda A Kotilinek; Marianne K Grant; Rose Pitstick; George A Carlson; Lorene M Lanier; Li-Lian Yuan; Karen H Ashe; Dezhi Liao
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

Review 2.  The role of tau kinases in Alzheimer's disease.

Authors:  Philip J Dolan; Gail V W Johnson
Journal:  Curr Opin Drug Discov Devel       Date:  2010-09

3.  Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3β in Alzheimer's disease.

Authors:  Tanusree Sen; Pampa Saha; Tong Jiang; Nilkantha Sen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-12       Impact factor: 11.205

4.  γ-Aminobutyric acid type A (GABAA) receptor activation modulates tau phosphorylation.

Authors:  Niko-Petteri Nykänen; Kai Kysenius; Prasanna Sakha; Päivi Tammela; Henri J Huttunen
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

5.  Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice.

Authors:  J M Fine; A M Baillargeon; D B Renner; N S Hoerster; J Tokarev; S Colton; A Pelleg; A Andrews; K A Sparley; K M Krogh; W H Frey; L R Hanson
Journal:  Exp Brain Res       Date:  2012-05-01       Impact factor: 1.972

6.  MARK2 Rescues Nogo-66-Induced Inhibition of Neurite Outgrowth via Regulating Microtubule-Associated Proteins in Neurons In Vitro.

Authors:  Yu-Chao Zuo; Nan-Xiang Xiong; Jian-Ying Shen; Hua Yu; Yi-Zhi Huang; Hong-Yang Zhao
Journal:  Neurochem Res       Date:  2016-07-28       Impact factor: 3.996

7.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

8.  Autophagy Induction and Accumulation of Phosphorylated Tau in the Hippocampus and Prefrontal Cortex of Adult C57BL/6 Mice Subjected to Adolescent Fluoxetine Treatment.

Authors:  Jorge A Sierra-Fonseca; Minerva Rodriguez; Anapaula Themann; Omar Lira; Francisco J Flores-Ramirez; Javier Vargas-Medrano; Bharathi S Gadad; Sergio D Iñiguez
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

9.  Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau.

Authors:  Isabelle Landrieu; Caroline Smet-Nocca; Laziza Amniai; Justin Vijay Louis; Jean-Michel Wieruszeski; Jozef Goris; Veerle Janssens; Guy Lippens
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

10.  Alzheimer's disease related markers, cellular toxicity and behavioral deficits induced six weeks after oligomeric amyloid-β peptide injection in rats.

Authors:  Charleine Zussy; Anthony Brureau; Emeline Keller; Stéphane Marchal; Claire Blayo; Brice Delair; Guy Ixart; Tangui Maurice; Laurent Givalois
Journal:  PLoS One       Date:  2013-01-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.